Bayer AG (BAYRY)
14.25
-0.09
(-0.63%)
USD |
OTCM |
Aug 26, 16:00
Bayer Enterprise Value : 95.17B for Aug. 26, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 95.17B |
| August 25, 2026 | 95.53B |
| August 24, 2026 | 94.66B |
| August 21, 2026 | 94.43B |
| August 20, 2026 | 94.66B |
| August 19, 2026 | 95.65B |
| August 18, 2026 | 94.64B |
| August 17, 2026 | 93.56B |
| August 14, 2026 | 93.56B |
| August 13, 2026 | 93.56B |
| August 12, 2026 | 93.84B |
| August 11, 2026 | 95.25B |
| August 10, 2026 | 94.98B |
| August 07, 2026 | 95.92B |
| August 06, 2026 | 95.45B |
| August 05, 2026 | 95.14B |
| August 04, 2026 | 94.11B |
| August 03, 2026 | 92.50B |
| July 31, 2026 | 93.76B |
| July 30, 2026 | 94.07B |
| July 29, 2026 | 92.78B |
| July 28, 2026 | 92.19B |
| July 27, 2026 | 91.79B |
| July 24, 2026 | 90.77B |
| July 23, 2026 | 90.77B |
| Date | Value |
|---|---|
| July 22, 2026 | 91.60B |
| July 21, 2026 | 92.62B |
| July 20, 2026 | 91.95B |
| July 17, 2026 | 93.41B |
| July 16, 2026 | 92.62B |
| July 15, 2026 | 92.74B |
| July 14, 2026 | 94.07B |
| July 13, 2026 | 94.82B |
| July 10, 2026 | 95.29B |
| July 09, 2026 | 95.92B |
| July 08, 2026 | 95.96B |
| July 07, 2026 | 95.80B |
| July 06, 2026 | 96.35B |
| July 02, 2026 | 98.85B |
| July 01, 2026 | 93.60B |
| June 30, 2026 | 93.01B |
| June 29, 2026 | 89.70B |
| June 26, 2026 | 90.61B |
| June 25, 2026 | 90.06B |
| June 24, 2026 | 82.55B |
| June 23, 2026 | 81.33B |
| June 22, 2026 | 80.82B |
| June 18, 2026 | 79.85B |
| June 17, 2026 | 80.43B |
| June 16, 2026 | 79.13B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck KGaA | 32.94B |
| Breakthrough Chemistry, Inc. | 1.389M |
| Cardiac Biotech Solutions, Inc. | 7.343M |
| Fresenius SE & Co. KGaA | 42.76B |
| Carl Zeiss Meditec AG | 3.273B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 266.26M |
| Revenue (Quarterly) | 12.64B |
| Total Expenses (Quarterly) | 12.39B |
| EPS Diluted (Quarterly) | 0.0648 |
| Gross Profit Margin (Quarterly) | 58.24% |
| Profit Margin (Quarterly) | 2.11% |
| Earnings Yield | -3.59% |
| Operating Earnings Yield | 13.06% |
| Normalized Earnings Yield | 3.466 |